Zhang AY, et al. - Experts re-analyzed molecular biomarkers to better predict PSA relapse, metastatic relapse and prostate cancer (PCa) death with extended follow-up. They then used biomarkers of significance to develop a combined prognostic model for clinical outcomes and validated it in a large independent cohort. For metastasis or PCa death, PSA relapse is not an adequate surrogate. AZGP1, Ki67 and PML were the only biomarkers associated with metastases, and only AZGP1 was associated with PCa death. A small benefit was offered by the dual biomarker signature of AZGP1 and Ki67 in predicting metastasis over AZGP1 alone.